Pain Management

Pharmacogenetic Testing in Pain Management

Individualizing Treatment of Pain
There is high variability in patient response to commonly prescribed pain medications (Argoff 2011). For example, two patients with the same diagnosis, prescribed the same drug and dose, often exhibit significantly different clinical responses. In fact, up to 40% of patients prescribed opioids, antidepressants, and antipsychotics are expected to be poor responders.1-5 Millennium Pharmacogenetic Testing (PGT)SM provides objective information that helps clinicians improve drug selection and dosing for individual patients, supporting a personalized approach to treatment.

Doctor helping patient decide Pain Management treatment using pharmacogenetic testing results
Clinician reviewing Pharmacogenetic Test to determine the right drug and right dose for their patient's Pain Management

Benefits of Millennium PGT in Pain Management

  • Assists clinicians in determining the right drug and right dose
  • Helps clinicians minimize trial and error prescribing, potentially shortening the time it takes for patients to feel better
  • Provides objective and clinically actionable results that may help clinicians make more effective prescribing decisions that are personalized for each patient

Request Information on Millennium PGT

Use the form below to request additional information about utilizing Millennium PGT in treating your patients.

Millennium Health representative answering questions about Pharmacogenetic Testing in Pain Management

  1. Spear BB, Heath-Chiozzi M, Huff J. Clinical application of pharmacogenetics. Trends Mol Med. May 2001;7(5):201-204.
  2. Xie H-G, Frueh FW. Pharmacogenomics steps toward personalized medicine. Personalized Medicine. 2005;2(4):325-337.
  3. Ross JS, Ginsburg GS. The Integration of molecular diagnostics with therapeutics; Implications for drug development
    and pathology practice. Am J Clin Pathol. 2003;119:26-36.
  4. Katz N, Rauck R, Ahdieh H, et al. A 12-week, randomized placebo-controlled trial assessing the safety and
    efficacy of oxymorphone extended release for opioid-naive patients with chronic low back pain. Curr Med Res
    Opin.2007;23:117 -128.
  5. Argoff CE. Clinical implications of opioid pharmacogenetics. Clin J Pain. 2010;26(1):S16-20.